Cencora 관리

관리 기준 확인 2/4

Cencora CEO는 Bob Mauch, Oct2022 에 임명되었습니다 의 임기는 2.08 년입니다. 총 연간 보상은 $ 7.70M, 12.7% 로 구성됩니다. 12.7% 급여 및 87.3% 보너스(회사 주식 및 옵션 포함). 는 € 12.31M 가치에 해당하는 회사 주식의 0.027% 직접 소유합니다. 12.31M. 경영진과 이사회의 평균 재임 기간은 각각 2.5 년과 9.5 년입니다.

주요 정보

Bob Mauch

최고 경영자

US$7.7m

총 보상

CEO 급여 비율	12.7%
CEO 임기	2.1yrs
CEO 소유권	0.03%
경영진 평균 재임 기간	2.5yrs
이사회 평균 재임 기간	9.5yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Bob Mauch 의 보수는 Cencora 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	US$2b
Jun 30 2024	n/a	n/a	US$2b
Mar 31 2024	n/a	n/a	US$2b
Dec 31 2023	n/a	n/a	US$2b
Sep 30 2023	US$8m	US$975k	US$2b
Jun 30 2023	n/a	n/a	US$2b
Mar 31 2023	n/a	n/a	US$2b
Dec 31 2022	n/a	n/a	US$2b
Sep 30 2022	US$6m	US$850k	US$2b
Jun 30 2022	n/a	n/a	US$2b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	n/a	n/a	US$2b
Sep 30 2021	US$6m	US$800k	US$2b
Jun 30 2021	n/a	n/a	-US$4b
Mar 31 2021	n/a	n/a	-US$4b
Dec 31 2020	n/a	n/a	-US$3b
Sep 30 2020	US$4m	US$700k	-US$3b
Jun 30 2020	n/a	n/a	US$2b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	n/a	n/a	US$649m
Sep 30 2019	US$4m	US$675k	US$855m
Jun 30 2019	n/a	n/a	US$956m
Mar 31 2019	n/a	n/a	US$930m
Dec 31 2018	n/a	n/a	US$1b
Sep 30 2018	US$3m	US$675k	US$2b

보상 대 시장: Bob 의 총 보상 ($USD 7.70M )은 German 시장( $USD 4.86M ).

보상과 수익: Bob 의 보상은 작년에 20% 이상 증가한 반면 회사 수익은 20% 이상 감소했습니다.

CEO

Bob Mauch (57 yo)

2.1yrs

테뉴어

US$7,697,850

보상

Dr. Robert P. Mauch, PharmD, Ph D., also known as Bob, is an Executive Vice President at Cencora, Inc. (formerly known as AmerisourceBergen Corporation) since February 2015 and served as its Group Presiden...

리더십 팀

이름	위치	테뉴어	보상	소유권
Steven Collis	Executive Chairman	13.5yrs	US$17.51m	0.19% € 87.8m
Robert Mauch	President	2.1yrs	US$7.70m	0.027% € 12.3m
James Cleary	Executive VP & CFO	6yrs	US$5.45m	0.070% € 32.1m
Elizabeth Campbell	Executive VP & Chief Legal Officer	3.2yrs	US$4.03m	0.0096% € 4.4m
Lazarus Krikorian	Senior VP	12.8yrs	데이터 없음	0.012% € 5.5m
Pawan Verma	Executive VP	less than a year	데이터 없음	데이터 없음
Bennett Murphy	Senior Vice President of Investor Relations	no data	데이터 없음	데이터 없음
Jennifer Dubas	Senior VP & Chief Compliance Officer	no data	데이터 없음	데이터 없음
Silvana Battaglia	Executive VP & Chief Human Resources Officer	5.8yrs	US$3.48m	0.011% € 5.1m
Richard Tremonte	EVP & President of U.S. Pharmaceuticals	less than a year	데이터 없음	데이터 없음
Ann Anaya	Senior VP and Chief Diversity Equity & Inclusion Officer	2.8yrs	데이터 없음	데이터 없음
Juan Guerra	EVP & President of International Business Group	less than a year	데이터 없음	데이터 없음

2.5yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 관리: ABG 의 관리팀은 경험 ( 2.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Steven Collis	Executive Chairman	13.5yrs	US$17.51m	0.19% € 87.8m
Robert Mauch	President	less than a year	US$7.70m	0.027% € 12.3m
Lauren Tyler	Independent Director	1.1yrs	데이터 없음	데이터 없음
Richard Gochnauer	Independent Director	16.2yrs	US$300.10k	0.011% € 5.2m
Mark M. Durcan	Lead Independent Director	9.2yrs	US$380.05k	0.010% € 4.6m
Lon Greenberg	Independent Director	11.5yrs	US$332.60k	0.0057% € 2.6m
Kathleen Hyle	Independent Director	14.5yrs	US$320.10k	0.011% € 4.9m
Dennis Nally	Independent Director	4.8yrs	US$375.36k	0.0052% € 2.4m
Ornella Barra	Director	9.8yrs	데이터 없음	데이터 없음
Henry McGee	Independent Director	20yrs	US$320.10k	0.0077% € 3.5m
Lorence Kim	Independent director	2.1yrs	US$397.33k	0.000090% € 41.1k
Redonda Miller	Independent Director	1.8yrs	US$311.82k	0.00080% € 365.4k

9.5yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 이사회: ABG 의 이사회는 경험(평균 재직 기간 9.5 년)으로 간주됩니다.

Cencora 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Cencora, Inc. Announces Management Appointments

Cencora, Inc. Elects Frank Clyburn as New Independent Director, Effective October 1, 2024

Cencora, Inc. Announces CEO Changes, Effective October 1, 2024

Cencora, Inc. Announces CEO Changes, Effective October 1, 2024

Cencora, Inc., Annual General Meeting, Mar 12, 2024

Cencora, Inc., Annual General Meeting, Mar 12, 2024

Recent updates

Cencora, Inc. Declares Quarterly Dividend, Payable on November 29, 2024

Cencora, Inc. (NYSE:COR) entered into a definitive agreement to acquire 85% stake in Retina Consultants of America from Webster Capital IV, L.P., fund managed by Webster Equity Partners, L.P. for $5.1 billion.

Cencora, Inc. Announces Management Appointments

Cencora, Inc. to Report Q4, 2024 Results on Nov 06, 2024

Cencora, Inc. Elects Frank Clyburn as New Independent Director, Effective October 1, 2024

Third quarter dividend of US$0.51 announced

Cencora, Inc. Declares Quarterly Cash Dividend, Payable on August 26, 2024

Cencora, Inc. to Report Q3, 2024 Results on Jul 31, 2024

Upcoming dividend of US$0.51 per share

Cencora, Inc. Declares Quarterly Cash Dividend on Common Share, Payable on May 24, 2024

Cencora, Inc. (NYSE:COR) announces an Equity Buyback for $2,000 million worth of its shares.

Cencora, Inc. to Report Q2, 2024 Results on May 01, 2024

Cencora, Inc. Reaffirms Guidance for Year 2024

Cencora, Inc. Announces CEO Changes, Effective October 1, 2024

Cencora, Inc. Announces CEO Changes, Effective October 1, 2024

Cencora’s FormularyDecisions Launches Payer Resource for Cell and Gene Therapy Products

First quarter dividend of US$0.51 announced

First quarter 2024 earnings released: EPS: US$3.01 (vs US$2.35 in 1Q 2023)

Cencora, Inc. Declares Quarterly Cash Dividend on Common Share, Payable on February 26, 2024

Cencora, Inc., Annual General Meeting, Mar 12, 2024

Cencora, Inc., Annual General Meeting, Mar 12, 2024

Cencora, Inc. to Report Q1, 2024 Results on Jan 31, 2024

Chairman recently sold €8.1m worth of stock

Insider recently sold €1.8m worth of stock

Cencora, Inc. Declares Quarterly Dividend, Payable November 27, 2023

Full year 2023 earnings released: EPS: US$8.62 (vs US$8.15 in FY 2022)

Cencora, Inc. to Report Q4, 2023 Results on Nov 02, 2023

Amerisourcebergen Corporation Elects Werner Baumann and Lauren Tyler to Its Board of Directors

Third quarter 2023 earnings released: EPS: US$2.37 (vs US$1.95 in 3Q 2022)

AmerisourceBergen Corporation Declares Quarterly Cash Dividend, Payable on August 28, 2023

AmerisourceBergen Corporation to Report Q3, 2023 Results on Aug 02, 2023

TPG Inc. (NasdaqGS:TPG), AmerisourceBergen Corporation (NYSE:ABC) and the management team of OneOncology, Inc. acquired OneOncology, LLC from General Atlantic Service Company, L.P. and others.

Executive VP & Chief Legal Officer recently sold €675k worth of stock

Second quarter 2023 earnings released: EPS: US$2.15 (vs US$2.62 in 2Q 2022)

Insider recently sold €282k worth of stock

Senior VP recently sold €832k worth of stock

First quarter 2023 earnings released: EPS: US$2.35 (vs US$2.15 in 1Q 2022)

An unknown buyer acquired Brazil specialty business from AmerisourceBergen Corporation (NYSE:ABC).

AmerisourceBergen Corporation, Annual General Meeting, Mar 09, 2023

AmerisourceBergen Corporation, Annual General Meeting, Mar 09, 2023

AmerisourceBergen Corporation to Report Q1, 2023 Results on Feb 01, 2023

Insider recently sold €129k worth of stock

Executive VP & Chief Strategy Officer recently sold €475k worth of stock

Full year 2022 earnings released: EPS: US$8.15 (vs US$7.48 in FY 2021)

AmerisourceBergen Corporation Elects Redonda Miller to Its Board of Directors, Effective January 1, 2023

AmerisourceBergen Corporation has completed a Follow-on Equity Offering in the amount of $1.546 billion.

Full year 2022 earnings released: EPS: US$8.15 (vs US$7.48 in FY 2021)

AmerisourceBergen Corporation Appoints Robert P. Mauch as Executive Vice President and Chief Operating Officer

AmerisourceBergen Corporation to Report Q4, 2022 Results on Nov 03, 2022

AmerisourceBergen Elects Lorence H. Kim, M.D., to Its Board of Directors

AmerisourceBergen Corporation (NYSE:ABC) agreed to acquire Pharmalex Holding Gmbh from AUCTUS Capital Partners AG for €1.3 billion.

AmerisourceBergen Corporation (NYSE:ABC) agreed to acquire Pharmalex Holding Gmbh for €1.28 billion.

Third quarter 2022 earnings released: EPS: US$1.95 (vs US$1.42 in 3Q 2021)

AmerisourceBergen Corporation Reports Goodwill Impairment for the Three Months Ended June 30, 2022

AmerisourceBergen to Launch Digital Therapeutics Platform to Facilitate Access to Innovative Products

AmerisourceBergen Corporation to Report Q3, 2022 Results on Aug 03, 2022

AmerisourceBergen Corporation (NYSE:ABC) announces an Equity Buyback for $1,000 million worth of its shares.

AmerisourceBergen Launches Clinical Trial Navigator to Bolster Equitable and Accessible Community-Based Research Opportunities Nationwide

Senior VP recently sold €743k worth of stock

An unknown buyer acquired 2.9% stake in AmerisourceBergen Corporation (NYSE:ABC) from Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) for $900 million.

Second quarter 2022 earnings released: EPS: US$2.62 (vs US$2.12 in 2Q 2021)

Amerisourcebergen Corporation Corporation Declares Quarterly Cash Dividend, Payable on May 31, 2022

Insufficient new directors

AmerisourceBergen Launches $150 Million Venture Capital Fund

AmerisourceBergen Corporation to Report Q2, 2022 Results on May 04, 2022

Insider recently sold €934k worth of stock

AmerisourceBergen, Cardinal Health and McKesson Approve Opioid Settlement Agreement

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

AmerisourceBergen Corporation Declares a Quarterly Cash Dividend, Payable on February 28, 2022